SYRE vs ARRY

Analysts rate Spyre Therapeutics, Inc.

(SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Spyre Therapeutics, Inc.

(SYRE) delivered a total return of -59. 9%, compared to -68. 0% for Array Technologies, Inc. (ARRY). Over 10 years, the gap is even starker: SYRE returned -66. 5% versus ARRY's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Spyre Therapeutics, Inc.

(SYRE) is the lower-risk stock at 2. 06β versus Array Technologies, Inc. 's 2. 32β — meaning ARRY is approximately 13% more volatile than SYRE relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Array Technologies, Inc.

grew EPS 62. 6% year-over-year, compared to 37. 7% for Spyre Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Array Technologies, Inc.

(ARRY) is the more profitable company, earning -4. 1% net margin versus -198. 3% for Spyre Therapeutics, Inc. — meaning it keeps -4. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARRY leads at 6. 6% versus -222. 8% for SYRE. At the gross margin level — before operating expenses — ARRY leads at 21. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARRY: 12.

9% to $9. 17.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Spyre Therapeutics, Inc.

(SYRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Array Technologies, Inc. (ARRY) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYRE: -66. 5%, ARRY: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SYRE (Healthcare) and ARRY (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SYRE is a mid-cap quality compounder stock; ARRY is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.